

Beneficiary Full Name: \_\_\_\_\_ Sponsor's SSN: \_\_\_\_\_-\_\_\_\_\_-\_\_\_\_\_

Date of Birth: \_\_\_\_\_ Beneficiary State of Residence: \_\_\_\_\_

Dear Provider,

Please complete the letter of attestation below and return as indicated on the additional information request letter.

TRICARE authorizes coverage for PROVENGE® (sipuleucel-T) in limited circumstances. PROVENGE is given through three separate IV infusions two weeks apart. Please provide the following information:

1. Is there evidence of metastatic prostate cancer to lymph nodes, bone and/or soft tissue?  Yes  No
2. Is there evidence of metastatic prostate cancer to liver, lung or brain?  Yes  No
3. Has the patient failed hormonal therapy?  Yes  No
4. Has the patient had bilateral orchiectomy (removal of the testes)?  Yes  No

Date of bilateral orchiectomy: \_\_\_\_\_

5. Is the patient taking medication to achieve chemical castration? (Examples of medications that meet this criteria include, Leuprolide (Lupron, Viodur, Eligard), Goserelin (Zoladex), Triptorelin (Trelstar), Histrelin (Supprelin LA, Vantas), and Degarelix (Firmagon).)  Yes  No

Name of Drug: \_\_\_\_\_

Date of Onset of Treatment: \_\_\_\_\_

6. Is the patient's testosterone at castrate level (serum testosterone < 50 mg/dl)?  Yes  No

Serum testosterone level: \_\_\_\_\_mg/dl.

Date of serum testosterone level: \_\_\_\_\_

7. Is there evidence of persistently elevated or rising PSA?  Yes  No

8. Is the PSA greater than or equal to five?  Yes  No

This document may contain information covered under the Privacy Act (5 USC §552a) and/or the Health Insurance Portability and Accountability Act (P.L.104-191) and its various implementing regulations and must be protected in accordance with those provisions. If you have received this correspondence in error, please notify 1-844-866-WEST (9378) at once and destroy the documents and any copies you have made.

PROVENGE is a registered trademark of Dendreon Corporation.

Authorizations and Referrals • PO Box 9108 • Virginia Beach, VA 23450-9108

TRICARE is a registered trademark of the Department of Defense, Defense Health Agency. All rights reserved. • HF0917x062 (03/18)

9. Is there evidence of increasing PSA on three successive reports?  Yes  No

PSA Result (1): \_\_\_\_\_ Date: \_\_\_\_\_

PSA Result (2): \_\_\_\_\_ Date: \_\_\_\_\_

PSA Result (3): \_\_\_\_\_ Date: \_\_\_\_\_

10. Is there evidence of progression of the metastatic disease?  Yes  No

Please explain: \_\_\_\_\_

11. Asymptomatic or minimally symptomatic (ECOG score 0 or 1)? (See table below)

ECOG score: \_\_\_\_\_

Eastern Cooperative Oncology Group (ECOG) Performance Status	
STATUS	GRADE
Fully active, able to carry on all pre-disease performances without restriction	0
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, for example, light house work or office work	1
Ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50 percent of waking hours	2
Capable of only limited self-care, confined to bed or chair more than 50 percent of waking hours	3
Completely disabled, cannot carry on any self-care or totally confined to bed or chair	4
Dead	5

12. Does the patient have a life-expectancy of at least six months?  Yes  No

I attest the information provided is true and accurate to the best of my knowledge. I understand Health Net Federal Services, LLC or designee may perform a routine audit and request the medical documentation to verify the accuracy of the information reported on this form.

Additional information: \_\_\_\_\_

Physician's printed name and title: \_\_\_\_\_

TIN: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_